Literature DB >> 23406986

Sector analysis of 125I permanent prostate brachytherapy provides a rapid and effective method of evaluating and comparing pre- and post-implant dosimetry.

Ahamed Badusha Mohamed Yoosuf1, Geraldine Workman, Monica M O'Toole, Margaret Straney, Rejina Verghis, Eoin Napier, Darren M Mitchell.   

Abstract

PURPOSE: To evaluate a sector analysis program in the assessment and comparison of pre- and post-implant dosimetric parameters during the development of an (125)I permanent prostate brachytherapy service. METHODS AND MATERIALS: A total of 50 consecutive men being treated with permanent prostate brachytherapy had dose-volume analysis in 12 sectors of their pre-implant ultrasound (USpre) and post-implant CT (CTpost) studies. Individual sectors were created by dividing prostate into three equal lengths, namely base, midgland, and apex. Each of these volumes was then divided into four axial sectors. Dosimetric parameters were compared in adjoining sectors within each study and between studies.
RESULTS: There were statistically significant differences between individual sectors on USpre and CTpost volumes with CTpost higher than USpre (p=0.001). Statistically significant differences were found in corresponding sectors on USpre and CTpost for all dosimetric parameters. The dosimetric parameters were significantly lower on CTpost in the anterior base and midgland (p=0.001) and significantly higher at the posterior apex and midgland (p=0.05). Dose homogeneity was demonstrated in adjoining sectors in all USpre and most adjoining sectors on CTpost.
CONCLUSIONS: Sector analysis allows rapid assessment of USpre and CTpost dosimetry. It offers a scientific method of identifying areas of increased and reduced dosing on CTpost when compared with USpre, providing a learning tool to refine dosimetric analysis and highlight sectors where implant quality could be improved.
Copyright © 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23406986     DOI: 10.1016/j.brachy.2012.08.007

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  4 in total

1.  Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate base.

Authors:  Austin N Kirschner; Vythialingam Sathiaseelan; Yunkai Zhang; James David; John A Kalapurakal
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

2.  Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life.

Authors:  Sarah O S Osman; Simon Horn; Darren Brady; Stephen J McMahon; Ahamed B Mohamed Yoosuf; Darren Mitchell; Karen Crowther; Ciara A Lyons; Alan R Hounsell; Kevin M Prise; Conor K McGarry; Suneil Jain; Joe M O'Sullivan
Journal:  Radiat Oncol       Date:  2017-03-14       Impact factor: 3.481

3.  Comparison of implant quality between intraoperatively built custom-linked seeds and loose seeds in permanent prostate brachytherapy using sector analysis.

Authors:  Norihisa Katayama; Mitsuhiro Takemoto; Atsushi Takamoto; Hiroki Ihara; Kuniaki Katsui; Shin Ebara; Yasutomo Nasu; Susumu Kanazawa
Journal:  J Radiat Res       Date:  2016-03-13       Impact factor: 2.724

4.  Importance of dynamic contrast enhanced magnetic resonance imaging for targeting biopsy and salvage treatments after prostate cancer recurrence.

Authors:  Josh Mason; Ese Adiotomre; Peter Bownes; Brendan Carey; Ann Henry
Journal:  J Contemp Brachytherapy       Date:  2018-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.